DS-6051B

• CAT Number: I006550
• CAS Number: 1505515-69-4
• Molecular Formula: C29H34FN5O5
• Molecular Weight: 551.60
• Purity: ≥95%
• Synonyms: DS-6051B; DS 6051B; DS6051B.;Unknown
• Target: NTRK/ROS1 inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: 3-[4-[(2R)-2-aminopropoxy]phenyl]-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine;hexanedioic acid
• InChI: InChI=1S/C23H24FN5O.C6H10O4/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18;7-5(8)3-1-2-4-6(9)10/h3-13,15-16H,14,25H2,1-2H3,(H,27,28);1-4H2,(H,7,8)(H,9,10)/t15-,16-;/m1./s1
• InChIKey: DORJQZDOULKINH-QNBGGDODSA-N
• SMILES: C[C@H](COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)N[C@H](C)C4=CC(=CC=C4)F)N.C(CCC(=O)O)CC(=O)O

DS-6051B（Cat No.:I006550）is a novel investigational antibody-drug conjugate (ADC) being explored for its potential use in cancer treatment. It is composed of an antibody targeting a specific antigen expressed on tumor cells, conjugated to a potent cytotoxic drug. The antibody portion allows DS-6051B to selectively deliver the cytotoxic agent directly to cancer cells, minimizing damage to healthy tissue. This targeted approach enhances the therapeutic efficacy and reduces side effects commonly seen with conventional chemotherapy. DS-6051B is currently being studied in clinical trials for various types of solid tumors, with promising results in early-phase studies.